Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches

My Linh T. Duong, Matthew R. Collinson-Pautz, E. Morschl, An Lu, Slawomir P. Szymanski, Ming Zhang, Mary E. Brandt, Wei Chun Chang, Kelly L. Sharp, Steven M. Toler, Kevin M. Slawin, Aaron E. Foster, David M. Spencer, J. Henri Bayle

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Use of chimeric antigen receptors (CARs) as the basis of targeted adoptive T cell therapies has enabled dramatic efficacy against multiple hematopoietic malignancies, but potency against bulky and solid tumors has lagged, potentially due to insufficient CAR-T cell expansion and persistence. To improve CAR-T cell efficacy, we utilized a potent activation switch based on rimiducid-inducible MyD88 and CD40 (iMC)-signaling elements. To offset potential toxicity risks by this enhanced CAR, an orthogonally regulated, rapamycin-induced, caspase-9-based safety switch (iRC9) was developed to allow in vivo elimination of CAR-T cells. iMC costimulation induced by systemic rimiducid administration enhanced CAR-T cell proliferation, cytokine secretion, and antitumor efficacy in both in vitro assays and xenograft tumor models. Conversely, rapamycin-mediated iRC9 dimerization rapidly induced apoptosis in a dose-dependent fashion as an approach to mitigate therapy-related toxicity. This novel, regulatable dual-switch system may promote greater CAR-T cell expansion and prolonged persistence in a drug-dependent manner while providing a safety switch to mitigate toxicity concerns.

Original languageEnglish
Pages (from-to)124-137
Number of pages14
JournalMolecular Therapy - Oncolytics
Volume12
DOIs
Publication statusPublished - Mar 29 2019

Fingerprint

Antigen Receptors
Cell- and Tissue-Based Therapy
T-Cell Antigen Receptor
Sirolimus
Xenograft Model Antitumor Assays
Safety
Caspase 9
Dimerization
Hematologic Neoplasms
Cell Proliferation
Apoptosis
Cytokines
T-Lymphocytes
Pharmaceutical Preparations
Neoplasms
Therapeutics

Keywords

  • apoptosis
  • CAR-T
  • cell therapy
  • costimulation switch
  • dimerizer
  • iMC
  • iRC9
  • rapamycin
  • rimiducid
  • safety switch

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Duong, M. L. T., Collinson-Pautz, M. R., Morschl, E., Lu, A., Szymanski, S. P., Zhang, M., ... Bayle, J. H. (2019). Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches. Molecular Therapy - Oncolytics, 12, 124-137. https://doi.org/10.1016/j.omto.2018.12.009

Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches. / Duong, My Linh T.; Collinson-Pautz, Matthew R.; Morschl, E.; Lu, An; Szymanski, Slawomir P.; Zhang, Ming; Brandt, Mary E.; Chang, Wei Chun; Sharp, Kelly L.; Toler, Steven M.; Slawin, Kevin M.; Foster, Aaron E.; Spencer, David M.; Bayle, J. Henri.

In: Molecular Therapy - Oncolytics, Vol. 12, 29.03.2019, p. 124-137.

Research output: Contribution to journalArticle

Duong, MLT, Collinson-Pautz, MR, Morschl, E, Lu, A, Szymanski, SP, Zhang, M, Brandt, ME, Chang, WC, Sharp, KL, Toler, SM, Slawin, KM, Foster, AE, Spencer, DM & Bayle, JH 2019, 'Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches', Molecular Therapy - Oncolytics, vol. 12, pp. 124-137. https://doi.org/10.1016/j.omto.2018.12.009
Duong, My Linh T. ; Collinson-Pautz, Matthew R. ; Morschl, E. ; Lu, An ; Szymanski, Slawomir P. ; Zhang, Ming ; Brandt, Mary E. ; Chang, Wei Chun ; Sharp, Kelly L. ; Toler, Steven M. ; Slawin, Kevin M. ; Foster, Aaron E. ; Spencer, David M. ; Bayle, J. Henri. / Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches. In: Molecular Therapy - Oncolytics. 2019 ; Vol. 12. pp. 124-137.
@article{983ad39942044c21a1dd59a516cdd253,
title = "Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches",
abstract = "Use of chimeric antigen receptors (CARs) as the basis of targeted adoptive T cell therapies has enabled dramatic efficacy against multiple hematopoietic malignancies, but potency against bulky and solid tumors has lagged, potentially due to insufficient CAR-T cell expansion and persistence. To improve CAR-T cell efficacy, we utilized a potent activation switch based on rimiducid-inducible MyD88 and CD40 (iMC)-signaling elements. To offset potential toxicity risks by this enhanced CAR, an orthogonally regulated, rapamycin-induced, caspase-9-based safety switch (iRC9) was developed to allow in vivo elimination of CAR-T cells. iMC costimulation induced by systemic rimiducid administration enhanced CAR-T cell proliferation, cytokine secretion, and antitumor efficacy in both in vitro assays and xenograft tumor models. Conversely, rapamycin-mediated iRC9 dimerization rapidly induced apoptosis in a dose-dependent fashion as an approach to mitigate therapy-related toxicity. This novel, regulatable dual-switch system may promote greater CAR-T cell expansion and prolonged persistence in a drug-dependent manner while providing a safety switch to mitigate toxicity concerns.",
keywords = "apoptosis, CAR-T, cell therapy, costimulation switch, dimerizer, iMC, iRC9, rapamycin, rimiducid, safety switch",
author = "Duong, {My Linh T.} and Collinson-Pautz, {Matthew R.} and E. Morschl and An Lu and Szymanski, {Slawomir P.} and Ming Zhang and Brandt, {Mary E.} and Chang, {Wei Chun} and Sharp, {Kelly L.} and Toler, {Steven M.} and Slawin, {Kevin M.} and Foster, {Aaron E.} and Spencer, {David M.} and Bayle, {J. Henri}",
year = "2019",
month = "3",
day = "29",
doi = "10.1016/j.omto.2018.12.009",
language = "English",
volume = "12",
pages = "124--137",
journal = "Molecular Therapy - Oncolytics",
issn = "2372-7705",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches

AU - Duong, My Linh T.

AU - Collinson-Pautz, Matthew R.

AU - Morschl, E.

AU - Lu, An

AU - Szymanski, Slawomir P.

AU - Zhang, Ming

AU - Brandt, Mary E.

AU - Chang, Wei Chun

AU - Sharp, Kelly L.

AU - Toler, Steven M.

AU - Slawin, Kevin M.

AU - Foster, Aaron E.

AU - Spencer, David M.

AU - Bayle, J. Henri

PY - 2019/3/29

Y1 - 2019/3/29

N2 - Use of chimeric antigen receptors (CARs) as the basis of targeted adoptive T cell therapies has enabled dramatic efficacy against multiple hematopoietic malignancies, but potency against bulky and solid tumors has lagged, potentially due to insufficient CAR-T cell expansion and persistence. To improve CAR-T cell efficacy, we utilized a potent activation switch based on rimiducid-inducible MyD88 and CD40 (iMC)-signaling elements. To offset potential toxicity risks by this enhanced CAR, an orthogonally regulated, rapamycin-induced, caspase-9-based safety switch (iRC9) was developed to allow in vivo elimination of CAR-T cells. iMC costimulation induced by systemic rimiducid administration enhanced CAR-T cell proliferation, cytokine secretion, and antitumor efficacy in both in vitro assays and xenograft tumor models. Conversely, rapamycin-mediated iRC9 dimerization rapidly induced apoptosis in a dose-dependent fashion as an approach to mitigate therapy-related toxicity. This novel, regulatable dual-switch system may promote greater CAR-T cell expansion and prolonged persistence in a drug-dependent manner while providing a safety switch to mitigate toxicity concerns.

AB - Use of chimeric antigen receptors (CARs) as the basis of targeted adoptive T cell therapies has enabled dramatic efficacy against multiple hematopoietic malignancies, but potency against bulky and solid tumors has lagged, potentially due to insufficient CAR-T cell expansion and persistence. To improve CAR-T cell efficacy, we utilized a potent activation switch based on rimiducid-inducible MyD88 and CD40 (iMC)-signaling elements. To offset potential toxicity risks by this enhanced CAR, an orthogonally regulated, rapamycin-induced, caspase-9-based safety switch (iRC9) was developed to allow in vivo elimination of CAR-T cells. iMC costimulation induced by systemic rimiducid administration enhanced CAR-T cell proliferation, cytokine secretion, and antitumor efficacy in both in vitro assays and xenograft tumor models. Conversely, rapamycin-mediated iRC9 dimerization rapidly induced apoptosis in a dose-dependent fashion as an approach to mitigate therapy-related toxicity. This novel, regulatable dual-switch system may promote greater CAR-T cell expansion and prolonged persistence in a drug-dependent manner while providing a safety switch to mitigate toxicity concerns.

KW - apoptosis

KW - CAR-T

KW - cell therapy

KW - costimulation switch

KW - dimerizer

KW - iMC

KW - iRC9

KW - rapamycin

KW - rimiducid

KW - safety switch

UR - http://www.scopus.com/inward/record.url?scp=85060737762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060737762&partnerID=8YFLogxK

U2 - 10.1016/j.omto.2018.12.009

DO - 10.1016/j.omto.2018.12.009

M3 - Article

AN - SCOPUS:85060737762

VL - 12

SP - 124

EP - 137

JO - Molecular Therapy - Oncolytics

JF - Molecular Therapy - Oncolytics

SN - 2372-7705

ER -